FinalNumber

[Ocugen Investor @kickstarterx10]

$OCGN

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

$OCGN #OCUGEN
We (Retail investors) hold 70% of the shares..... we are the owners....don't forget that. Our voice counts, stop complaining....make sure your voice is heard but stop b...tching.

Come to next spaces and talk and make sure company understands your concerns!

[Ocugen @Ocugen]

Honored to join the U.S. @CommerceGov Certified Trade Mission to Singapore with https://t.co/MFNdMesYmg, connecting with investors and industry leaders to advance cross-border collaboration. Looking forward to continuing the conversation globally. @drsmusunuri #TradeMission

[Ocugen @Ocugen]

Phase 2 Update: A 31% reduction in GA lesion growth was observed with #OCU410 (medium dose) and a 27% EZ preservation in treated v. control supporting medium dose as optimal in Phase 3. #GeographicAtrophy #PatientImpact

Latest corp. presentation: https://t.co/hIYAlBqgZQ

[Ocugen @Ocugen]

#OCU410 Phase 2 ArMaDa topline results show:
• 31% ↓ GA lesion growth at 12 months vs. control
• ~2X treatment effect vs. approved therapies
• EZ preservation + favorable safety
A one-and-done approach to reduce treatment burden.
🔗https://t.co/hIYAlBqgZQ #GeographicAtrophy

[Shankar Musunuri @drsmusunuri]

One step closer to serving Stargardt patients! Big thanks to our dedicated Ocugen team.

[Ocugen Patient Engagement @OcugenPE]

During #RetinitisPigmentosaAwarenessMonth, the need for new treatments is clear. We are advancing #OCU400, our lead modifier gene therapy candidate, and plan to begin the BLA submission this year. Learn about Manny’s journey: https://t.co/4fa0P6l4mG

#GeneTherapy #Biotech

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

$OCGN #OCUGEN tough day, hope this will ease the pain.
Next Gen new product in the pipeline!!!

[Ocugen Patient Engagement @OcugenPE]

Ocugen shared positive 12-month Phase 2 data from ~50% of patients for #OCU410 in #GA, showing a 46% reduction in lesion growth vs. control and new Phase 1 data showing 60% slower EZ loss with no OCU410-related serious adverse events to date.

Learn more: https://t.co/TImVtaLvQ5

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇 👇
We found something extremely interesting! Don't want to overwhelm the today's presentations, so will be sharing with you closer to the end of the day. It is extremely interesting and super positive next generation new technology, so happy for #Ocugen!!!

[Shankar Musunuri @drsmusunuri]

It is exciting to share 12-month results from the Phase 1 GARDian1 trial for #OCU410ST in individuals with early to advanced Stargardt disease, where no treatment currently exists. #Biotech

[Ocugen Patient Engagement @OcugenPE]

We're enrolling patients in the U.S., ages 18+, in our Phase 1 clinical trial for #OCU200 with the potential to benefit all #DME patients, including those who do not respond to approved therapies.

Learn more: 610-871-2528 | NCT05802329

#Biotech #ClinicalTrial #Ocugen

[Ocugen Patient Engagement @OcugenPE]

This week, CEO @drsmusunuri met with Dr. Oz in DC and spoke about our novel modifier #genetherapy platform at the @Oppenheimer Summit in NY. We ended the week with an inspiring Patient Panel where #OCU400 and #OCU410ST trial participants shared hope where it once didn’t exist.

[Shankar Musunuri @drsmusunuri]

Had a productive meeting with Dr. Oz, @CMSGov @DrOz

#MakeAmericaSeeAgain

[Shankar Musunuri @drsmusunuri]

Thank you Congressman @PeteSessions and BioTech Caucus members for championing this legislation. This Act will make a significant impact to American Biotech!

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

[Ocugen @Ocugen]

In @ThePharmaSource, Ocugen’s CSO shares insight into the novel approach of modifier gene therapy to address large patient populations, along with updates on the Company’s progress toward 3 BLAs in 3 years.

Read more: https://t.co/USzPLtA5jF

#Ocugen #GeneTherapy

[Shankar Musunuri @drsmusunuri]

Happy to share 3Q business highlights!! Thank you team @Ocugen!

[Shankar Musunuri @drsmusunuri]

Encouraging to show that our gene therapy in clinical trials for dAMD and Stargardt has potential to target Autism - high unmet medical need @autismspeaks

[Ocugen @Ocugen]

Read the latest from @FrontNeurosci! Our authors share how nuclear hormone receptors including RORA could potentially open new doors for #Autism treatment. RORA modifier #genetherapy is in clinical development for dAMD and Stargardt diseases.

Read more: https://t.co/I99t8SGJtJ